A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma

Sponsor
Mayo/MMRC

Protocol Number
MC1582 MMRC-061

To Learn More Call
201-510-0910

Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma

Sponsor
Georgetown

Protocol Number
Georgetown 2016-0002 (COTA U01)

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

Phase I study of SGN-CD352A in patients with relapsed or refractory multiple myeloma

Sponsor
Seattle Genetics

Protocol Number
Seaettle Genetics SGN352-001

To Learn More Call
201-510-0910

Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies

Sponsor
MMRF

Protocol Number
MMRF-002

To Learn More Call
201-510-0910

A Ph